The US Food & Drug Administration (FDA) has approved the use of the botulinum neurotoxin Xeomin® (incobotulinumtoxinA) as a first-line treatment of blepharospasm in adults, as announced in a press release from Merz. Blepharospasm is a focal dystonia that causes muscles around the eyes to contract involuntarily. Individuals with blepharospasm may experience excessive blinking, light […]
We need your valuable input. Please consider participating in a brief, anonymous survey to help the Dystonia Medical Research Foundation better understand your experiences with botulinum neurotoxin injections. Individuals who are diagnosed with dystonia and receive treatment in the USA are welcome to participate. Click here to participate. Any questions, please contact us.
The Center for Neurosciences at The Feinstein Institute for Medical Research conducts one of the nation’s leading brain imaging programs directed by neuroscientist, David Eidelberg, MD. The program is internationally recognized for developing new techniques to identify and measure patterns and circuits of brain function in people with disorders such as Parkinson’s disease, Huntington’s disease, […]
The Dystonia Medical Research Foundation (DMRF) announced Abhimanyu Mahajan, MD, MHS, University of Cincinnati, as the latest recipient of the DMRF Clinical Fellowship Award to support training in the diagnosis and treatment of movement disorders with special expertise in dystonia. Dr. Mahajan’s mentor is Alberto J. Espay, MD, MSc, Professor of Neurology, Director, James J. […]
The DMRF is pleased to announce the appointment of Joel S. Perlmutter, MD as Scientific Director. He is pictured (R) with Scientific Director Emeritus, Mahlon Delong, MD. Dr. Perlmutter is the Elliot H. Stein Family Professor of Neurology and Professor of Radiology, Neuroscience, Physical Therapy and Occupational Therapy; and Head of the Movement Disorders Section […]
This article originally appeared in the Dystonia Dialogue. Drug discovery and development efforts are an important part of the Dystonia Medical Research Foundation’s (DMRF) multi-faceted science strategy. “The dystonia community cannot wait for pharmaceutical and biotech companies to necessarily get interested in dystonia on their own,” explains Jan Teller, MA, PhD, DMRF’s Chief Scientific Advisor. […]
The Dystonia Medical Research Foundation (DMRF) announced its latest post-doctoral fellowship awards to advance research toward improved dystonia treatments and a cure. For more than 40 years, the DMRF has funded dystonia science and created opportunities for young investigators to establish careers in this growing field. Dystonia is the third most common movement disorder, affecting […]
A new study led by Antonio Pisani, MD, PhD of University of Rome Tor Vergata, offers new insights into the role of dopamine in DYT1 dystonia. It may also explain why DYT1 dystonia patients vary in their response to dopamine-boosting medications such as levodopa. The work of Dr. Pisani and his group may inspire new drug […]